Phillip Paul Minar (Phillip Minar)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Topics

Combination Therapy

Patients With Inflammatory Bowel Disease

Ulcerative Colitis

Top Venues

Inflammatory bowel diseases

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Phillip Paul Minar, Ruben J Colman, Nanhua Zhang, Tomoyuki Mizuno, Alexander A Vinks
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ open 14 (3) (2024)
Ruben J Colman, Stephanie A Vuijk, Ron A A Mathôt, Johan Van Limbergen, Maria M E Jongsma, Marco W J Schreurs, Phillip Paul Minar, Lissy de Ridder, Geert R A M D'Haens
Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics. Inflammatory bowel diseases (2024)
Jessica R Allegretti, Liliana G Bordeianou, Oriana M Damas, Samuel Eisenstein, Ruby Greywoode, Phillip Paul Minar, Siddharth Singh, Sabrina Harmon, Eugene Lisansky, Myisha Malone-King, Nicole S Litwin, Alandra Weaver, Caren A Heller, Alan C Moss, Jeremy Adler
Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory bowel diseases 30 (Supplement_2) (2024)
Phillip Paul Minar, Ruben J Colman, Nanhua Zhang, Tomoyuki Mizuno, Alexander A Vinks
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ open 14 (3) (2024)
Ruben J Colman, Stephanie A Vuijk, Ron A A Mathôt, Johan Van Limbergen, Maria M E Jongsma, Marco W J Schreurs, Phillip Paul Minar, Lissy de Ridder, Geert R A M D'Haens
Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics. Inflammatory bowel diseases (2024)
Jessica R Allegretti, Liliana G Bordeianou, Oriana M Damas, Samuel Eisenstein, Ruby Greywoode, Phillip Paul Minar, Siddharth Singh, Sabrina Harmon, Eugene Lisansky, Myisha Malone-King, Nicole S Litwin, Alandra Weaver, Caren A Heller, Alan C Moss, Jeremy Adler
Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory bowel diseases 30 (Supplement_2) (2024)
Phillip Paul Minar, Ruben J Colman, Nanhua Zhang, Tomoyuki Mizuno, Alexander A Vinks
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ open 14 (3) (2024)
Phillip Paul Minar, Ruben J Colman, Nanhua Zhang, Tomoyuki Mizuno, Alexander A Vinks
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ open 14 (3) (2024)
Ruben J Colman, Phillip Paul Minar
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply. Alimentary pharmacology & therapeutics 57 (5) (2023)
Ruben J Colman, Phillip Paul Minar
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply. Alimentary pharmacology & therapeutics 57 (5) (2023)
Ruben J Colman, Tomoyuki Mizuno, Keizo Fukushima, David B Haslam, Jeffrey S Hyams, Brendan Boyle, Joshua D Noe, Geert R A M D'Haens, Johan E Van Limbergen, Kelly Chun, Jane Yang, Lee A Denson, Nicholas J Ollberding, Alexander A Vinks, Phillip Paul Minar
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Alimentary pharmacology & therapeutics (2022)
Ruben J Colman, Abigail Samuels, Tomoyuki Mizuno, Nieko Punt, Alexander A Vinks, Phillip Paul Minar
Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease. Inflammatory bowel diseases (2022)
Ruben J Colman, Ye Xiong, Tomoyuki Mizuno, Jeffrey S Hyams, Joshua D Noe, Brendan Boyle, Geert R D'Haens, Johan E Van Limbergen, Kelly Chun, Jane Yang, Michael J Rosen, Lee A Denson, Alexander A Vinks, Phillip Paul Minar
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Alimentary pharmacology & therapeutics 55 (5) (2021)